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Background: Although mammary cancer (MC) is the most common malignant neoplasia in women, the mortality
for this cancer has decreased principally because of early detection and the use of neoadjuvant chemotherapy. Of
several preparations that cause MC regression, doxorubicin (DOX) is the most active, first-line monotherapeutic.
Nevertheless, its use is limited due to the rapid development of chemoresistance and to the cardiotoxicity caused
by free radicals. In previous studies we have shown that supplementation with molecular iodine (I2) has a powerful
antineoplastic effect in methylnitrosourea (MNU)-induced experimental models of MC. These studies also showed a
consistent antioxidant effect of I2 in normal and tumoral tissues.
Methods: Here, we analyzed the effect of I2 in combination with DOX treatment in female Sprague Dawley rats
with MNU-induced MC. In the first experiment (short) animals were treated with the therapeutic DOX dose (16
mg/kg) or with lower doses (8 and 4 mg/Kg), in each case with and without 0.05% I2 in drinking water. Iodine
treatment began on day 0, a single dose of DOX was injected (ip) on day 2, and the analysis was carried out on
day 7. In the second experiment (long) animals with and without iodine supplement were treated with one or two
injections of 4 mg/kg DOX (on days 0 and 14) and were analyzed on day 56.
Results: At all DOX doses, the short I2 treatment induced adjuvant antineoplastic effects (decreased tumor size and
proliferating cell nuclear antigen level) with significant protection against body weight loss and cardiotoxicity
(creatine kinase MB, cardiac lipoperoxidation, and heart damage). With long-term I2, mammary tumor tissue became
more sensitive to DOX, since a single injection of the lowest dose of DOX (4 mg/Kg) was enough to stop tumor
progression and a second DOX4 injection on day 14 caused a significant and rapid decrease in tumor size,
decreased the expression of chemoresistance markers (Bcl2 and survivin), and increased the expression of the
apoptotic protein Bax and peroxisome proliferator-activated receptor type gamma.
Conclusions: The DOX-I2 combination exerts antineoplastic, chemosensitivity, and cardioprotective effects and
could be a promising strategy against breast cancer progression.
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The two factors responsible for most breast cancer-
related deaths are the ability of cancer cells to
metastasize and to develop resistance to anti-cancer
therapies. Indeed, resistance to chemotherapy is a
major obstacle to successful treatment of breast cancer
[1,2]. Anthracycline antibiotics are among the most ef-
fective and commonly used anticancer drugs, and
doxorubicin (DOX) in particular is often the first
choice to treat mammary cancer. Nevertheless, its use
has been limited due to the rapid development of
chemoresistance and cardiomyopathic side effects
[1,3]. The therapeutic activity of DOX results from its
intercalating into DNA, thereby inhibiting topoisomerase II
and preventing DNA and RNA synthesis [4,5]. With
respect to chemoresistance, it is known that DOX-resistant
cells exhibit: 1) diminished Topoisomerase II expression,
2) increased production of calcium-dependent protein
transglutaminases and of integrins involved in membrane
stabilization, and 3) increased expression of anti-apoptotic
messengers like Bcl2, Bxl, or survivin [2,6,7]. The protein
survivin (Surv), the smallest member of the inhibitor of
apoptosis protein (IAP) family, is expressed and required
for normal fetal development but is generally absent in
adult tissues. However, re-expression of Surv is ob-
served in numerous human cancers where its presence
is associated with enhanced proliferation, metastasis,
and a poor prognosis [8].
Short-term adverse effects of DOX occurring within
2–3 days of administration include nausea, vomiting,
neutropenia, alopecia, and arrhythmias [9]. A long-term
side effect is the cardiomyophathy associated with con-
gestive heart failure [10,11]. This chronic cardiotoxicity
is likely related to iron oxidation and oxygen free radical
formation rather than to antineoplastic mechanisms of the
drug, since cardiomyocytes are minimally replicating cells
[10]. DOX typically induces dilated cardiomyophathy with
microscopic features including myofibrillar loss, mito-
chondrial and interstitial edema, fibroplasias, etc. Clinical
serum biomarkers such as creatine kinase MB (CK-MB) or
troponins may increase and serve as important, early
predictors of cardiotoxicity [12,13].
Low incidences of mammary cancer and cardiovascu-
lar disease have been associated with the high iodine
intake in Asian, as compared to Western populations
(5280 vs 209 μg /day). Seaweeds, such as wakame, nori,
or mekabu, are widely consumed in Asian countries and
contain high quantities of iodine in several chemical
forms [14,15]. In recent years several research groups
including ours have demonstrated that iodine per se acts
as an antioxidant in the whole organism and participates
in the physiology and/or pathology of organs that cap-
ture iodine, such as thyroid, mammary gland, prostate, and
stomach [16-19]. In mammary gland, supplementation withmolecular iodine (I2), but not iodide (I
-), alleviates
human mastalgia and exerts potent antineoplastic and
apoptotic effects on animal and human cancer. When
administered over periods of weeks up to years, mod-
erately high concentrations of I2 supplements (3–6
mg/day) have no deleterious effects on thyroid or gen-
eral health [20-22]. Although the cellular mechanisms
through which iodine exerts these effects have not
been elucidated in depth, two hypotheses have been
proposed: a direct action involving the antioxidant/oxi-
dant properties of iodine, and an indirect effect
through iodolipid formation. In the case of antioxi-
dant/oxidant effects, two sets of data have been
obtained showing that: a) at low or moderate concen-
trations, I2 significantly reduces lipid oxidation either
by competing with reactive oxygen species (ROS) for
various cellular components, or by neutralizing HO
radicals, and b) at high concentrations, iodine acts as a
direct oxidant, dissipating the mitochondrial mem-
brane potential, thereby triggering mitochondrion-
mediated apoptosis [18,23-25]. The indirect effect was
originally postulated for thyroid tissue and involves the
formation of iodolipids such as 6-iodo-5-hydroxy-
8,11,14-eicosatrienoic acid (also called 6-iodolactone;
6-IL) or alpha-iodohexadecanal derived from arachi-
donic acid (AA) or eicosapentaenoic acid, respectively
[26]. Both iodolipids exert apoptotic effects [27], and
our group has demonstrated that 6-IL is present in
mammary cancer cells after I2 supplement and is a
functional ligand of peroxisome proliferator-activated
receptor (PPAR) type gamma (PPARγ) [28-30]. PPARs
are ligand-activated transcription factors, and three
subtypes -- PPAR alpha, PPAR beta, and PPAR gamma --
have been identified [31]. Although originally de-
scribed as molecular regulators of lipid metabolism,
PPARγ were recently shown to play an important role
in cell proliferation, differentiation, and apoptosis in
many cancer cell lines including breast, prostate, and
non-small-cell lung cancer [32]. Moreover, PPARγ
activation potentiates the cytotoxic effect of chemo-
therapeutic agents such as DOX by inhibiting the ex-
pression of anti-apoptotic proteins like Bcl2 and Surv
[7] or by delaying the epithelial-mesenchymal transi-
tion [33].
In the present work we evaluated the effect of
I2 supplement in combination with DOX on the
methylnitrosourea (MNU)-induced mammary cancer
model. Our results show that a 7-day I2 supplement
exerts a significant antineoplastic adjuvant effect with
DOX as well as significant cardioprotection, whereas a
56-day iodine treatment is associated with enhanced
DOX sensitivity, increased Bax and PPARγ, and
decreased Bcl2 and Surv expression suggesting that
iodine, through PPARγ expression/activation, induces
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chemoresistance.Results
Short-term DOX-I2 combination
Figure 1 summarizes body weight and tumor growth for
animals given the three doses of DOX with and without
I2 supplement. The data show that high concentrations
of DOX (16 and 8 mg) were associated with dose-
dependent weight loss and decreased tumor growth, but
the DOX4 and I2 groups showed no changes in body
weight gain. DOX4 alone did not decrease tumor
growth, whereas the I2 group exhibited a 30% reduction
of tumor size. When DOX and I2 were administered
together, a significant and consistent protection against
body weight loss was observed in groups treated with
high doses of DOX (16 and 8 mg/Kg), and tumor size
reduction was significantly greater with I2 than without
I2 in the DOX16 and DOX4 groups.Figure 1 Effect of molecular iodine (I2) and different doses of doxoru
Animals with tumors (2–3 cm3) received single injections of DOX and 0.05%
injections). Data are expressed as the mean ± SD (n = 10). * Indicates p < 0.0Mechanisms involved in the antineoplastic effect of
DOX and iodine were analyzed in animals treated with
the therapeutic dose of DOX (DOX16 groups). The
results showed that either DOX16 or I2 treatments
significantly decreased the proliferation rate (measured
by PCNA), its combination achieves a higher response
than separately (Figure 2). Only I2 groups (I2 and
DOX16-I2) exhibited significant increases in the apoptotic
index (measured by Bax/Bcl2, Figure 3). No changes in
Surv expression were observed at any dose, and only the
group treated with both components (DOX16-I2) showed
significant increases in PPARγ expression.
Cardioprotective effect
DOX16 and DOX8 treatments resulted in significant,
dose-dependent increases in serum CK-MB activity,
whereas DOX4 or I2 groups did not show any changes
(Figure 4A). The co-administration of DOX and I2 was
accompanied by a significant attenuation of the CK-MB
increases generated by the high doses of DOX (DOX-16-bicin (DOX) on body weight and tumor size in MNU-induced rats.
I2 treatment (drinking water; beginning 2 days before the DOX
5 compared to control or **compared with DOX group.
Figure 2 Proliferation rate. Immunohistochemical presence of PCNA-positive cells in tumors from control and DOX16-treated animals with and
without iodine supplement for one week. PCNA-positive cells were revealed with diaminobenzidine (brown stain) and counterstained with
hematoxylin (purple stain). Data are expressed as the mean ± SD (n = 6). Means with different letters indicate statistically significant
differences (p < 0.05).
Figure 3 Short-term effect on gene expression. Animals with tumors (2–3 cm3) received a single injection of DOX16 and were treated with
0.05% I2 for one week. mRNA expression was measured by qPCR. β-actin mRNA was amplified to check for RNA quantity and integrity. The
experiments were repeated three times with independent RNA samples. Values are expressed as mean ± SD. Means with different letters indicate
statistically significant differences (p < 0.05).
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Figure 4 Cardiac responses. CK-MB serum concentration (A), cardiac lipoperoxidation [malondialdehyde (MDA); B] and catalase activity
[U* = μmoles of H2O2 consumed/min; C] were measured in MNU-treated animals injected with saline (Control) or DOX exposed or not to
0.05% I2 for one week. Values are expressed as mean ± SD. Means with different letters indicate statistically significant differences (p < 0.05).
Basal group in CK-MB corresponds to control animals without MNU treatment.
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protection was related to its antioxidant effects,
lipoperoxidation and catalase enzyme expression were
analyzed in heart tissue. Figure 4B shows that the high
levels of cardiac lipoperoxidation observed in DOX16-
and DOX8-treated animals were prevented when the
animals were supplemented with iodine. In contrast,
catalase expression did not change, indicating no partici-
pation of this enzyme (Figure 4C). These findings agree
with microscopic analysis showing significantly less heart
injury in DOX16-I2 than in DOX16 animals, where the
principal damage observed was in mitochondria, sarco-
meres, and fibers (Additional file 1). Based on the
in vitro FRAP assay, the reductive capacity of molecular
iodine is 10 times higher than that of ascorbic acid, and
30 to 60 times that of other chemical forms of iodine
(Figure 5).
Long-term DOX4/I2 combination
In order to analyze the efficacy of long-term I2 supplement
(56 days) as a means of preventing the chemoresistance to
DOX, we designed a second series of experiments usingone or two injections of the lower dose of DOX (DOX4).
Figure 6 shows that DOX4 alone exerts a modest and tran-
sitory antineoplastic effect after both the first and the sec-
ond injections, with tumor growth resuming a few days
later. In the case of I2 supplement, alone or with one initial
DOX4 injection (I2 or DOX4/I2), a significant and rapid de-
crease is observed in the tumor growth (first 7 days), but
tumor size remains constant after 14 days. In contrast, the
injection of one DOX4 dose after 14 days of I2 supplement
(I2 + DOX4) or a second injection of DOX4 in the DOX4/
I2 group exerts a significant adjuvant antineoplastic effect
that almost eliminates the tumor mass after 42 days in both
groups (Figure 6). Comparison of the groups DOX4 +
DOX4 vs. DOX4/I2 + DOX4 shows that repeated, low
concentrations of DOX induce increases in the expres-
sion of both apoptotic (Bax) and anti-apoptotic
messengers (Bcl2 and survivin), suggesting the devel-
opment of chemoresistance (Figure 7). In contrast,
iodine supplement blocks the induction of anti-
apoptotic messengers and favors the induction of
positive apoptotic signals (Bax and PPARγ expression).
The significant increase in the Bax/Bcl2 index in
Figure 5 Iodine antioxidant power. The antioxidant capacity of
different chemical forms of iodine was analyzed with the ferric
reducing/antioxidant power assay (FRAP). Lugol: solution of I2:KI (1:3).
Ascorbic acid was used as positive control. Values are expressed as
mean ± SD (n = 4).
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ity that correlates with the marked reduction of tumor
mass observed in this group.
Discussion
Mammary cancer is the most common malignant neo-
plasia in women worldwide and although many different
types of cytotoxic drugs have been developed for its
treatment, all are accompanied by adverse effects and in
many cases by the development of drug resistance [1].
Thus, there is increasing interest in natural productsFigure 6 Long-term effect on tumor size (% change). Animals with tum
injections of saline (Control) or DOX4 with and without I2 supplement, and
DOX4 (DOX4); I2 alone (I2); DOX4 + I2 (DOX4/I2); DOX4 + second injection (d
DOX4 (I2 + DOX4), and DOX/I2 with the second injection of DOX4 on day 1
* Indicates p < 0.05 compared to control, **compared with I2 and DOX4/I2that can complement conventional medicine. The
present study was designed to evaluate the antineoplastic
and cardioprotective effects of iodine in conjunction
with DOX, the most effective and commonly used che-
motherapeutic drug to treat mammary cancer [34]. Our
data corroborated previously reported antineoplastic and
cardiotoxic effects of DOX [13] and showed that iodine
per se exhibited a significant antineoplastic effect in
MNU-induced mammary cancer [22,29]. We also found
that I2 potentiated the cytotoxic effect of DOX, inhibited
the development of chemoresistance to it, and provided
significant cardioprotection.
To understand the mechanisms involved in DOX-I2
action, we utilized a variety of molecular techniques to
label and measure selected markers. In the present
study, we demonstrate that either DOX or I2 alone was
able to reduce proliferation by about 50%, but there was
no potentiation when the two treatments were adminis-
tered together. This finding suggests that cellular arrest
could not be the prime mechanism involved in the adju-
vant effect of I2. In contrast, when the apoptotic index
(Bax/Bcl2) was analyzed, iodine had a significant adju-
vant effect at both high and low DOX doses. Moreover,
the finding that PPARγ expression increased only in
I2-supplemented animals suggests that DOX potentiates
the PPARγ overpexpression mediated by I2. It is well
documented that DOX impairs the synthesis or replica-
tion of DNA, resulting in the apoptotic activation of the
Bax-caspase pathway [12] and increased expression
of anti-apoptotic messengers like Bcl2 and Surv [8],
suggesting a complex interaction between apoptotic and
anti-apoptotic signaling. Indeed, some authors have pro-
posed that the long-term imbalance in this interactionors (2–3 cm3) received one (day 0) and/or two (days 0 and 14)
tumor size was measured at 56 days. Single injection on day 0 of
ay 14) of DOX4 (DOX4 + DOX4); I2 with only the day 14 injection of
4 (DOX4/I2 + DOX4). Vertical arrows indicated DOX4 injections days.
groups.
Figure 7 Long-term I2 effect on gene expression. Animals with tumors (2–3 cm
3) received two injections of saline (Control) or DOX4 without
(DOX4 + DOX4) or with continuous I2 supplement (DOX4/I2 + DOX4) for 56 days. mRNA expression was measured by qPCR. β-actin mRNA was
amplified to check for RNA quantity and integrity. The experiments were repeated three times with independent RNA samples. Values are
expressed as mean ± SD. Means with different letters are statistically significantly (p < 0.05).
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occurs when the anti-apoptosis signaling prevails [7].
Molecular iodine administration is accompanied by spe-
cific increases in PPARγ and Bax, as well as significant
decreases or no changes in Bcl2 and Surv expression.
These pro-apoptotic patterns of iodine action have been
described previously in both in vitro and in vivo models
and agree with the well-documented regulation of the
Bax/Bcl2-caspase family by PPARγ [19,32]. Although a
specific PPAR response element has not been identified
for these genes, activation of PPARγ provokes a signifi-
cant decrease in the expression of Blc2 and Surv in
mammary tumor cell lines MCF-7 and MDA-MB231
[7]. The direct participation of PPARγ was confirmed
using the specific antagonist GW9662 and by the lack of
inhibition observed in cells transfected with a PPARγ
dominant negative plasmid. The wide spectrum of ef-
fects exerted by PPARγ has been explained by its mul-
tiple activation pathways and transcriptional regulation
of target genes: 1) classical activation to form a
heterodimer with the retinoid X receptor (RXR) that
binds to specific recognition sites, named the peroxi-
some proliferator response elements (PPRE), located
within the promoter regions of PPAR-responsive genes
(ligand-dependent transactivation); 2) in the absence of
ligand, PPARγ and RXR could also be associated with
transcriptional co-repressor complexes such as nuclear
receptor co-repressor (N-CoR) or SMRT (silencing
mediator of retinoid and thyroid receptors), which have
deacetylation activity (HDAC) and mediate transcription
repression (ligand-independent repression), or 3) the
ligand-PPARγ complex could repress transcription byinhibiting the activities of other transcription factors,
such as members of the NFκB and AP-1 families
(ligand-dependent transrepression) [31]. It was proposed
that this last repression pathway might down-regulate
the expression of Bcl2 and Surv [7].
Several studies suggest that the cardiotoxicity induced
by DOX is mediated by reactive oxygen species (ROS)
[9]. Two different mechanisms have been identified. The
first implicates semiquinone-type free radicals produced in
the NADPH-dependent reductase pathway. The second
mechanism includes a non-enzymatic reaction of DOX
with iron that generates H2O2; the peroxide, in turn, forms
hydroxyl radicals that cause oxidative injury in cellular sys-
tems [10]. In one study, the activities of three enzymes cap-
able of detoxifying activated oxygen were determined in
both heart and liver; although glutathione peroxidase activ-
ity was similar in both tissues, cardiac muscle contained
150 times less catalase and nearly four times less super-
oxide dismutase than liver. These results showing the low
antioxidant resources of the heart, together with its very ac-
tive metabolism, led the authors to suggest that the heart is
particularly vulnerable to damage by free radicals generated
in the presence of DOX [35,36]. Our present results cor-
roborate the DOX cardiotoxicity: the highest values for CK-
MB and LPO activity were in the DOX16 and DOX8
groups. DOX cardiotoxicity was attenuated, however, in the
corresponding groups supplemented with I2. The specific
mechanism involved in the cardioprotective effect of I2 is
not known; indeed, this is the first report that iodine could
have this effect. It is well known that other organs besides
the thyroid gland are capable of taking up iodine, although
heart has not been included in the list [17]. However, in a
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can produce thyroid hormone under ischemia-like condi-
tions. They have shown that thyroglobulin, DUOX1,
DUOX2, the sodium-iodide symporter, pendrin, thyroid
peroxidase, and the thyroid-stimulating-hormone receptor
are transiently up-regulated during this injury, suggesting
that this allows cardiomyocytes to initiate cell-protective
mechanisms even before local circulation is re-established.
Whether a similar mechanism is triggered in these cells
during DOX injury has not been explored; however, the
high reductive capacity of I2 (FRAP assay) and its prevent-
ive effect against heart lipoperoxidation observed in the
DOX16-I2 group suggest that iodine might be acting by a
direct antioxidant mechanism, neutralizing the free radicals
and preventing them from damaging other biomolecules.
Indeed, this powerful antioxidant effect has been previously
described as a systemic effect on whole organism (17), and
is corroborated in the present study by the significant pro-
tection against body weight loss observed when animals
with high Dox doses (8 and 16 mg) were treated with I2.
Another main finding of our work was the long-term
effect of I2 in animals that received the lowest dose of
DOX (DOX4) once or at two different times. We ob-
served that DOX4 alone (one or two injections) could
impede tumor growth only in a modest and transitory
manner and that the tumoral “escape” was accompanied
by increases in anti-apoptotic markers like Bcl2 and
Surv. In contrast, the long-term I2 supplement (at least
14 days) with one or two DOX4 doses significantly
enhanced the sensitivity to DOX, decreasing tumor size
and blocking the increase of anti-apoptotic markers,
suggesting that the pathways to chemoresistance were
blocked. Moreover, the significant increases in PPARγ
expression in this group, led us to propose that I2 affects
the expression and activation of these receptors. The
participation of PPARγ in chemoresistance has been
extensively documented: PPARγ activation potentiated
the cytotoxic effect of chemotherapeutic agents such as
DOX by 1) inhibiting the expression of anti-apoptotic
proteins like Bcl2 and Surv [7], and 2) inducing differen-
tiation, decreasing cell proliferation, and increasing
E-cadherin and beta-catenin expression, indicating the
possible interference of PPARγ with processes like the
epithelial-mesenchymal transition implicated in acquisi-
tion of the invasive phenotype [33,38,39].
Conclusions
A robust body of evidence supports the notion that
moderately high concentrations of molecular iodine
exert apoptotic effects in several cancer cells as well as
general antioxidant actions in the organism. In the
present work we demonstrated that, through activation
of PPARγ, long-term I2 treatment increases the tumor
sensitivity to DOX, inhibits chemoresistance, and exertscardioprotective effects, allowing a four-fold reduction
in the therapeutic dose of DOX. These results, together
with the adjuvant neoplastic effects of I2, lead us to
propose Doxorubicin in combination with I2 supple-




The studies were performed on virgin female Sprague
Dawley (200 g) rats from the vivarium of the Instituto
de Neurobiología, UNAM-Juriquilla. Rats were housed
in a temperature-controlled room (21 ± 1°C) with a
12-h/12-h light/dark schedule. Food (Purina rat chow;
Ralston Purina Co., St. Lous, MO) and water were
available ad libitum. All of the procedures followed
UNAM and Use Committee Guidelines.
Carcinogen, iodine, and DOX treatments
At 6 weeks of age, rats were treated to induce mammary
tumors with a single ip injection of 50 mg/kg MNU
(Sigma, St. Louis, MO; dissolved in 0.9% saline, pH 5.0
and activated by heating to 50-60°C) [40]. Rats were
weighed and palpated for tumors every week beginning
1 month after MNU exposure. When the tumors grew
to 2–3 cm3 (12–16 weeks later), the animals were di-
vided into the following groups: Control, DOX16 (16
mg/kg), DOX8 (8 mg/kg), DOX4 (4 mg/kg); DOX16 +
0.05% I2 (DOX16-I2), DOX8 + 0.05% I2 (DOX8-I2),
DOX4 + 0.05% I2 (DOX4-I2), and 0.05% I2 (I2). Each
dose of DOX (Pharmacia & Upjohn) was administered
in a single ip injection. The I2 stock solution is a satu-
rated solution (1.33 mM) of iodine sublimate (J.T. Baker;
Edo. de México, Mexico) in distilled water, and the con-
centration of 0.05% was confirmed by titration with so-
dium thiosulfate (40). The drinking water I2 solution
was delivered in amber bottles that were changed every
two days. After correction for sublimation (<30%), we
estimated that animals consume an intake equivalent to
that of Asian populations (5–7 mg/day). The I2 supple-
ment in drinking water began 2 days before DOX and
continued for another 5 days until the animals were
sacrificed. To determine the long-term effect of DOX4-I2
treatment, a second series of experiments was carried out,
with or without I2 being supplemented continuously for 56
days, and DOX4 was administered by ip injection on day 0
and/or on day 14. The treatment groups were designed as:
single injection day 0 DOX4 (DOX4); I2 alone (I2); DOX4
+ I2 (DOX4/I2); DOX4 + second injection at day 14 of
DOX4 (DOX4 +DOX4); I2 with only the day 14 injection
of DOX4 (I2 +DOX4), and DOX/I2 with the second injec-
tion of DOX4 on day 14 (DOX4/I2 +DOX4). A tumor was
defined as a discrete palpable mass recorded for least two
consecutive weeks. Tumor sizes were measured using
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Immunohistochemistry of proliferating cell nuclear
antigen (PCNA)
Five-μm sections of mammary tumors from rats with or
without DOX16 or I2 treatment were deparaffinized,
rehydrated, and subjected to antigen retrieval (10 mM so-
dium citrate) at 80°C for 20 min. After cooling at room
temperature, sections were treated with 0.3% hydrogen per-
oxide to block endogenous peroxidase activity. Non-
specific binding was blocked with 2% non-fat dry milk in
20% fetal bovine serum-PBS solution (1 hr at 37°C). Sec-
tions were incubated at room temperature for 30 min in a
humid chamber with mouse monoclonal anti-rat PCNA,
clone PC10 (DakoCytomation, Carpinteria, CA),
diluted 1:150). Immune complexes were visualized by goat
anti-mouse-immunoglobulin, peroxidase labeled (EnVi-
sion™ + System, peroxidase, DakoCytomation, Carpinteria,
CA). Diaminobenzidine (DAB) was used as the chromogen
to generate a brown precipitate after reaction with peroxid-
ase. Sections were counterstained with hematoxylin, rinsed,
dehydrated, and mounted with Entellan (Merck, Darm-
stadt, Germany). Tumor sections were incubated without
either the primary or secondary antibody to test for anti-
body specificity. A brown stain over the nucleus identified
PCNA-positive cells. Labeling indices were obtained by
counting the number of labeled cells among at least 500
cells per region, and 5 randomly selected regions were
analyzed.
Real time PCR
PPARγ, Bax, Bcl2, and Surv expression were analyzed by
quantitative real time PCR (qPCR) from tumors after
short- (7 day) or long- (56 day) term treatment. Total
RNA was obtained using the TRIzol reagent (Life
Technologies, Inc., Carlsbad, CA) dissolved in RNAase-
free water (50 μL), and stored at −70°C. The extracted
RNA (2 μg) was reverse transcribed using oligo-
deoxythymidine. In order to eliminate genomic DNA
contamination, we carried out the RT assay for each in-
dividual sample, and as control we used one tube that
contained an aliquot from a pool of all samples but no
transcriptase enzyme (−RT). We ran a standard PCR for






Surv NM022274 aagccacttgtcccagcttand the -RT control. The sequence detector system
Roto-Gene 3000 (Corbett Research, Mortlake, NSW,
Australia) was used to perform qPCR with SYBRgreen
as a marker for DNA amplification. The reaction was
carried out with 1 μL of cDNA template and the qPCR
supermix-UDG kit (Invitrogen), using 40 cycles of three-
step amplification (94°C for 30 s, 55–60°C for 30 s, 72°C
for 30 s) and the gene-specific primers listed in Table 1.
PCR generated only the expected specific amplicon,
which was demonstrated in each case by the melting
temperature profile (dissociation curve) and by electro-
phoresis of 5 μL of the PCR product through a 2%
agarose gel containing ethidium bromide in TAE buffer.
No PCR products were observed in the absence of tem-
plate. Gene expression was calculated using the D-cycle
threshold (Dct) method and normalized to the content
of β-actin, a non-regulated housekeeping gene [42]. The
coefficient of variation for this gene was less than 15% in
all RT-PCR assays, indicating that the significant changes
observed in the different groups correspond to changes
in the experimental genes.
Creatine kinase MB (CK-MB) and catalase activity
Serum levels of CK-MB were assayed to evaluate cardiac
damage, using the commercial kit Humazym M-Test
(Human GmbH-65205 Wiesbaden, Germany). Cardiac
catalase activity was assayed using the method described
by Aebi [43]. Heart tissue was homogenized in assay
buffer (50 mM KH2PO4, pH 7), and the homogenates
were centrifuged at 6000 × g at 4°C for 20 min. The
supernatant was diluted with 3 volumes of the assay buf-
fer. Specific activity is expressed as μmol H2O2/min/mg
protein. Protein was determined using the Bradford
method (Bio-Rad protein assay; Hercules, CA) with bo-
vine serum albumin (BSA) as standard.
Cardiac lipoperoxidation
The concentrations of metabolites related to lipoperoxi-
dation were quantified in heart tissue by the thiobarbituric
acid reaction and expressed as nanomoles of malo-
ndialdehyde (MDA) per mg protein [44]. All manipulations
were made rapidly on ice to avoid nonspecific peroxidation.
Some modifications to the original method were intro-
duced. To determine basal levels, a sample of hom-
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pH 7.4; incubation was stopped by adding 1.5 mL 20%
acetic acid (adjusted to pH 3.5 with KOH) and 1.5 mL
0.8% thiobarbituric acid. Samples were kept for 45
min in a boiling water bath, and 1 mL 2% KCl was
added to each sample at the end of the incubation. The
colored complex formed was extracted with butanol-
pyrimidine (1:1, v/v) and detected at 532 nm. Protein
was quantified by the Bradford method as above.
Iodine antioxidant effect
Iodine antioxidant power was measured in vitro using the
ferric reducing/antioxidant power assay (FRAP) method
reported by Benzie and Strain [45] with some modifica-
tions. The FRAP reagent was freshly prepared prior to each
analysis by combining 300 mM sodium acetate buffer pH
3.6, 10 mM 2,4,6-tripyridyl-s-triazine in 40 mM HCl, and
20 mM ferric chloride in the proportions 10:1:1 (v/v/v).
A series of ascorbic acid standards was freshly prepared for
each analysis. The FRAP assay was carried out in a
microplate (Dynex Technologies, Inc) Individual wells
were manually loaded with sodium acetate buffer
(60 μL) and either ascorbic acid standards or samples
(60 μL), after which 240 μL FRAP reagent was added
to each well; absorbance at 620 nm was determined 4
min later. Different chemical forms of iodine were
analyzed and compared to ascorbic acid as standard.
Statistical analysis
The data are expressed as mean ± SD. Differences be-
tween experimental groups were analyzed using a one-
way ANOVA and Tukey’s honest significant difference
test. Differences with p < 0.05 were considered statisti-
cally significant.
Histological heart microscopy
Heart fragments were fixed at 4°C by immersion in fixative
solution containing 3% glutaraldehyde either in cacodylate
or phosphate buffer at pH 7.2 and processed by routine
electron microscopy techniques [46]. Epon 1-μm thick sec-
tions were obtained with a glass knife and thin sections
with a diamond knife either in a Reichert Um03 or RMC
ultramicrotome. Thin sections were contrasted with uranyl
acetate and lead citrate. One-μm sections were stained with
1% toluidine blue in 0.1 M sodium borate solution at alka-
line pH. Thin sections were observed in a JEOL 1010 elec-
tron microscope operated at 80 KV.
Additional file
Additional file 1: Cardiac electron micrography. Animals with tumors
(2–3 cm3) received a single injection of DOX16 and/or 0.05% I2 treatment
(drinking water) for 7 days. A, mitochondrion and fiber damage; B,
laminary rearrangement.Abbreviations
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